InTRoDuCTIon
Crohn's disease (CD) is a chronic inflammatory gastrointestinal disease occurring mainly in young people. Inflammation may affect any portion of the digestive system from the mouth to the anus, with characteristic pathological lesions such as intestinal stenosis or fistulas. In addition, complications may develop in other organs such as joints, skin, or eyes. The main symptoms include digestive symptoms such as diarrhoea and abdominal pain, and symptoms derived from complications such as fever, weight loss, and malnutrition. The disease progresses with relapses and remission periods often impairing social life. 1 2 Medical treatment for CD includes the administration of 5-amino salicylic acid, steroids, immunomodulators, anti-tumour necrosis factor (TNF) antibodies, anti-interleukin (IL)-12/23p40 antibody, and antibiotics, with the choice of treatment depending on the location and severity of disease. 3 4 The development of new therapeutic drugs has increased treatment options, but many patients are resistant to the available medication, and approximately 50% of patients requiring surgical operation for symptomatic relief within 10 years of diagnosis. 5 6 New treatment strategies are required for refractory CD resistant to existing therapies.
Mesenchymal stem cells (MSC) are multipotent, plastic adherent stromal cells present in a variety of tissues, including bone marrow, fat, and umbilical cords. MSCs are considered a potential cell source for regenerative medicine because they can secrete a variety of humoral anti-inflammatory factors that are Open Access required for tissue regeneration. 7 Reports have suggested the efficacy of MSCs for CD treatment. 8 We have demonstrated that a large number of MSCs can be obtained from the amnion, which is discarded after delivery, and that intravenous administration of human amnion-derived MSCs (AMSC) alleviates inflammatory bowel disease in dextran sulfate sodium-induced colitis and trinitrobenzene sulfonic acid-induced colitis rat models. 9 10 We believe that the anti-inflammatory effects of AMSCs are responsible for those effects.
Therefore, the present study has been designed to investigate the safety and efficacy of intravenous administration of AMSCs (AM01) in patients with treatment-resistant CD, in a phase I/II clinical trial.
METhoDS AnD AnAlySIS Study design
This study is a phase I/II, dual-centre, open-label, uncontrolled, dose-response clinical trial (figure 1), currently under way at the Hokkaido University Hospital in Sapporo, Japan, and in the Hyogo College of Medicine College Hospital in Nishinomiya, Japan. This trial is registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN000029841). The total study period is 2 years, from November 2017 to October 2019. 
Study population

Sample size
Because this trial is a phase I/II pilot study, each group will comprise three patients to examine the safety of the AM01 injection according to a dose escalation protocol. The sample size of the safety test is based on the traditional 3+3 dose escalation design.
11 Safety in the high-dose group will be evaluated after confirmation of safety in the three cases of the low-dose group. After confirmation of safety in the three cases of the high-douse group, additional three cases will be enrolled for the high-dose group to explore the efficacy.
Statistical analysis
A full statistical analysis plan will be written prior to data collection. Objective outcome measures will be scored according to standard methodology, with prior knowledge of the limitations of the small sample size. We will measure CDAI, SESCD, and IBDQ to analyse the effectiveness of AMSCs and prepare figures showing changes in those scores for each patient. 
Open Access
The characteristics of AMSCs This study uses AMSCs (AM01) supplied by Dr Kenichi Yamahara, 12 and approved for clinical studies by the Pharmaceuticals and Medical Devices Agency (PMDA, Tokyo, Japan). The phenotypes of AM01 are characterised by their positivity for CD73, CD90, and CD105, and by their negativity for haematopoietic-associated marker CD45 and epithelial cell-associated marker CD326.
Preparation of AMSCs
After obtaining informed consent, human fetal membranes were obtained during caesarean deliveries, and the amnion was separated from the chorion by peeling. AMSCs were isolated and expanded by digestion using several Good Manufacturing Practice (GMP)-grade enzymes. The cells were then seeded in plastic cell culture chambers with basal medium supplemented with adult bovine-derived platelet-rich plasma (NeoSERA, Japan Biomedical, Otofuke, Japan, https://www. japanbiomedical. jp). The cultures were maintained at 37°C in a humidified atmosphere of 95% air and 5% CO 2 . Next, the cells were harvested via trypsinisation, and AMSCs were packaged into frozen bags and stored under −130°C. Cells were further cultured after thawing the frozen bags, passaged, harvested, and packaged into frozen bags and stored below −130°C as product doses. Quality testing for AM01 included assessments for cell appearance, purity, viable cell number, viability, and presence of bacteria, virus, mycoplasma or endotoxin contamination. We followed the GMP guidelines for regenerative medicine of the PMDA during the whole manufacturing process.
Intervention
A dose of 1.0×10 6 cells/kg will be administered intravenously to patients in the low-dose group on days 0 and 7, and a dose of 4.0×10 6 cells/kg will be administered intravenously to those in the high-dose group on days 0 and 7.
Endpoints of the study Primary endpoint ► Identification of adverse events related to acute infusion toxicity (within 24 hours after infusion). Safety assessment and reporting of adverse events Patients will be hospitalised from day −1 through day 8. Adverse events and safety assessments will be conducted during AM01 administration, immediately after AM01 administration, 15 min, 30 min, 1 hour, 2 hours, 4 hours, 6 hours, and 24 hours after AM01 administration (table 1) , and at every visit after AM01 administration. The investigator will report adverse events and protect patients who participate in this trial. Adverse events and their associations with injected materials will be reported according to the Common Terminology Criteria for Adverse Events v4.0 of the Japan Clinical Oncology Group grading.
Secondary endpoints
Severe adverse events that result in life-threatening and prolonged disability conditions will be reported to the institutional review board by the investigator.
Dropping out policy
Participants have the right to discontinue participating in the trial at any time without stating any reason. Moreover, participants may be excluded because of medical or other reasons as follows: ► Inability to continue participation because of relocation. ► Violation of inclusion criteria. ► A situation in which injecting AM01 is deemed impossible due to adverse events. ► A situation in which injection of AM01 is deemed impossible due to product quality problems. ► Participants who fulfil the exclusion criteria for the second injection. ► An investigator may decide to exclude a patient because of health and well-being concerns.
Follow-up of study
The patients will be hospitalised from day −1 through day 8 and will visit the hospital thereafter during the 2nd, 4th, 8th, 12th, 16th, 20th, 24th, 28th, 36th, 44th, and 52nd weeks ( 
DISCuSSIon
Patients with CD with active disease lesions often experience decreased quality of life. Anti-TNF antibodies, especially infliximab, have had a great impact on CD treatment because of their ability to induce and maintain remission. However, about one-third of the prescribed patients do not respond to induction therapy (primary non-response), and 25%-40% of those who initially respond lose the response during treatment (secondary loss of response). 13 Switching to another anti-TNF-α antibody (adalimumab) or to the anti-IL12/23p40 antibody (ustekinumab) is an alternative treatment for these patients, but there are no additional possibilities for patients that are refractory to these treatments. The main mechanisms of MSCs for tissue regeneration and repair are believed to involve differentiation into target cells, paracrine effects by secretion of humoral factors, and immune regulation.
14 Among those mechanisms, when MSCs are administered systemically, the latter two are considered to be particularly active. 15 Clinical trials using MSCs to treat patients with CD have been conducted; and administration of autologous bone marrow-derived MSC treatment for refractory luminal CD has been reported to be safe and feasible resulting in Open Access ameliorated clinical symptoms and endoscopic findings without any critical side effects. 16 In addition, administration of allogeneic bone marrow-derived MSCs to patients with biologic therapy-refractory CD improved the CDAI and the Crohn's Disease Endoscopic Index of Severity. 17 Moreover, allogeneic transplantation of MSCs obtained from the bone marrow of healthy donors and from umbilical cords obtained during normal deliveries was safe and may have contributed to the clinical improvement seen in patients with refractory CD and ulcerative colitis 18 In this study, we are using AMSCs, obtained from human amnion specimens. AMSCs are promising cells because large amounts can be obtained from an amnion, and amnions can be obtained after delivery without any invasive procedures inflicted upon the donors.
This study has the limitation of its small sample size. Although the study population has been determined by traditional 3+3 dose escalation with modification, we will not be able to draw general conclusions for the effects of AMSCs. However, this study is the first in-human clinical trial to use AMSCs. The results of this pilot study will help to determine a safe dose of AMSCs for clinical use. In addition, our results and experience will help plan for future clinical trials using AMSCs for CD treatment.
In conclusion, our study is the first to investigate the safety and efficacy of AMSCs used for treating CD. We expect that our results will expand knowledge for more efficient and convenient methods to overcome the limits of the available CD treatments.
Dissemination plan
At the end of the study, a report describing the study results will be submitted for publication in an appropriate journal after completion of data analysis.
